Updates on newborn screening for Spinal muscular atrophy and Pompe disease
Together with Muscular Dystrophy Canada (MDC) we are pleased to invite you to a webinar on Newborn screening for Spinal muscular atrophy and Pompe disease. This webinar is primarily targeted at Canadian clinicians, academics, and trainees with an interest in neuromuscular disease. This is a clinical/academic webinar with support from Sanofi through a restricted educational sponsorship; there is no involvement or influence from industry on program content. NMD4C and MDC are providing organizational and technical support.
Chair:
- Dr. Alex MacKenzie | Professor of Pediatrics, uOttawa | Pediatrician, CHEO | Senior Scientist, CHEO Research Institute
Speakers and Agenda:
4 years of newborn screening for SMA in Ontario
- Dr. Kristin Kernohan | Molecular Geneticist, Newborn Screening Ontario, CHEO
A new understanding of Pompe disease in the era of NBS
- Dr. Priya Kishnani | Professor of Pediatrics and Molecular Genetics & Microbiology, Division Chief, Medical Genetics, Duke University Medical Center
Learning Objectives:
- Understand what is detected and not detected for Spinal muscular atrophy (SMA) as part of newborn screening
- Summarize the Ontario experience in screening for SMA
- Recognize early features of LOPD identified by NBS
- How to comprehensively evaluate babies with LOPD identified via NBS
The NMD Rounds & Educational Webinars is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.